Opinion|Videos|December 17, 2024
Practical Considerations in Metastatic NSCLC: Access and Timing of Testing
Author(s)Heather A. Wakelee, MD, FASCO, Jacob Sands, MD
Panelists discuss strategies for clinicians without access to in-house molecular testing, focusing on how to ensure appropriate turnaround times when outsourcing tests and share insights on the typical timeline for receiving biomarker testing results at their respective institutions.
Advertisement
Episodes in this series
- Dr Wakelee to Dr Sands: For clinicians who may not have access to “in-house” molecular testing at their institutional or community site and have to outsource these tests, are there any potential strategies to employ to ensure an appropriate turnaround time?
- Dr Sands to Dr Wakelee: At your institution, how long does it typically take to receive the results for biomarker testing?
Advertisement
Related to this article
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Sonrotoclax monotherapy produced durable responses in Chinese patients with relapsed/refractory mantle cell lymphoma.
lan M. Thompson Jr., MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
UCSF Health’s Adam Blaisdell, MD, PhD, has been selected as an IGNITE fellow by the Cancer Research Institute.
BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Disparities Progress Report and what oncologists can do to combat them.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
Exploring the Rationale for 5-Alpha Reductase Inhibitors in Prostate Cancer Prevention and Active Surveillance
3
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
4
The OncFive: Top Oncology Articles for the Week of 8/2
5